Outset Medical, Inc. (OM)
After hours:
| Previous close | 3.5850 |
| Open | 3.9100 |
| Bid | 4.3100 x 500 |
| Ask | 4.3700 x 300 |
| Day's range | 3.9050 - 4.5400 |
| 52-week range | 1.9200 - 22.4700 |
| Volume | |
| Avg. volume | 1,249,103 |
| Market cap | 223.958M |
| Beta (5Y monthly) | 1.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Outset Medical to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
SAN JOSE, Calif., June 03, 2024--Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 45th annual Healthcare conference on Wednesday, June 12, 2024, at 11:20 a.m. Eastern time.
- Business Wire
Outset Medical Reports First Quarter 2024 Financial Results
SAN JOSE, Calif., May 08, 2024--Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance
SAN JOSE, Calif., May 06, 2024--Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with prefiltration, an innovative optional accessory for the Tablo® Hemodialysis System.
